SCHEDULE 13G/A: AdvisorShares Trust Discloses 0.79% Stake in PSYENCE BIOMEDICAL LTD. via Schedule 13G Amendment

AdvisorShares Trust has filed an amended Schedule 13G, disclosing a beneficial ownership of 0.79% of PSYENCE BIOMEDICAL LTD.'s Common Shares as of December 31, 2024.

Summary

• AdvisorShares Trust, a Delaware-organized entity, has filed an Amendment No. 1 to Schedule 13G regarding its holdings in PSYENCE BIOMEDICAL LTD.
• The filing indicates that AdvisorShares Trust beneficially owns 26,923.75 Common Shares of PSYENCE BIOMEDICAL LTD.
• This ownership represents 0.79% of the total class of securities.
• AdvisorShares Trust holds sole voting power and sole dispositive power over all 26,923.75 shares.
• The filing was made pursuant to Rule 13d-1(b), indicating that AdvisorShares Trust is an investment adviser.
• The event requiring this filing occurred on December 31, 2024.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, providing no positive or negative performance indicators or strategic insights. The sentiment is neutral.

Future Outlook

This document is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure by an investment adviser, AdvisorShares Trust, detailing its passive ownership stake in PSYENCE BIOMEDICAL LTD., a company operating in the biomedical sector. Such filings provide transparency on institutional holdings but do not typically reflect strategic shifts or operational performance within the biomedical industry.

Stakeholder Impact

• Shareholders: Provides transparency on institutional ownership, confirming AdvisorShares Trust's passive stake in the company.

Key Dates

Keywords

PSYENCE BIOMEDICAL LTD., AdvisorShares Trust, Schedule 13G, Beneficial Ownership, Common Shares, SEC Filing, Investment Adviser, Equity Stake, Public Disclosure